Designed drug candidate significantly reduces HIV reactivation rate
HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the ...
Jul 8, 2015
0
49